Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-lymphocyte surface antigen Ly-9 (also known as CD229 or SLAMF3) is a type I transmembrane glycoprotein belonging to the signaling lymphocytic activation molecule (SLAM) family within the immunoglobulin superfamily. It is expressed on the surface of T and B lymphocytes, thymocytes, and natural killer (NK) cells, where it functions as a homophilic adhesion receptor and modulates immune cell activation, differentiation, and homeostasis. In healthy tissues, Ly-9 acts as a regulator of lymphocyte tolerance and development, but it is highly and stably overexpressed in hematological malignancies, particularly multiple myeloma and various B-cell lymphomas. Because of its uniform expression on malignant plasma cells and myeloma-propagating stem cells, Ly-9 has emerged as a highly promising therapeutic target. Current drug development efforts primarily focus on chimeric antigen receptor (CAR) T-cell therapies, including monospecific CD229 CAR-T cells and bicistronic constructs targeting both BCMA and CD229 to prevent antigen-escape relapses. Additionally, monoclonal antibodies targeting Ly-9 are being investigated for their ability to induce antibody-dependent and complement-dependent cytotoxicity in cancer, as well as for depleting pathogenic B-cell subsets in autoimmune conditions like Sjögren's syndrome.
Chimeric antigen receptor T-cell therapy, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and inhibition of homophilic interaction
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-lymphocyte surface antigen Ly-9 (LY9).